Madrigal公司从中国瑞博生物引进六种siRNA以充实MASH治疗管线。
Madrigal pads MASH pipeline with six siRNAs from China's Ribo
生命科学资讯
生物技术与制药领域的最新动态
古布拉成立风险投资部门；加莱克托完成2.75亿美元融资。
Gubra forms venture unit; Galecto's $275M offering
一柜子心电图机如何揭示药企临床试验成本问题
How a closet full of EKG machines illustrates pharma’s clinical trial cost problem
奥斯卡健康预计2026年将迎来爆发式增长，但伴随风险。
Oscar Health expects explosive growth for 2026, but it comes with a risk
事后直播：生物技术与FDA的关系是否濒临破裂？
Post-Hoc Live: Is biotech’s relationship with the FDA at a breaking point?
Upstream Bio宣布verekitug在重度哮喘二期试验中取得积极数据。
Upstream Bio says verekitug delivered positive data in Phase 2 severe asthma trial
Moderna指控FDA改变标准，拒绝审查其流感疫苗。
Moderna accuses FDA of shifting standard as agency refuses flu shot review
同构科技宣布其新型AI药物设计引擎取得重大突破。
Isomorphic claims major advance with new AI drug design engine
ILiAD融资1.15亿美元推进百日咳疫苗研发。
ILiAD raises $115M round to advance whooping cough vaccine
艾伯维与阿斯利康在路易斯安那州340B合同药店争议中上诉失败。
AbbVie, AstraZeneca lose appeal in Louisiana 340B contract pharmacy fight
美国国立卫生研究院因安全问题叫停大型中风研究中的低剂量拜瑞妥试验组。
NIH stops low-dose Xarelto arm of large stroke study due to safety concerns
阿斯利康能否实现800亿美元营收目标？
Is AstraZeneca on track to meet its $80B revenue target?
诺和与希姆斯之争的余波
The fallout from Novo vs. Hims
上海Cascade获7200万美元融资，专注研发MASH、肥胖及糖尿病药物。
Shanghai's Cascade gets $72M to pursue MASH, obesity and diabetes drugs
Nektar公布湿疹治疗一年期成果显著；辉瑞终止营养不良试验。
Nektar posts one-year eczema success; Pfizer ends malnutrition trial
CSL首席执行官保罗·麦肯齐卸任，戈登·纳勒被任命为临时CEO。
CSL’s Paul McKenzie out, as Gordon Naylor named interim CEO
阿斯利康减肥药二期试验告捷，关键癌症试验延期。
AstraZeneca’s obesity pill hits in Phase 2, key cancer trials pushed back
“疯狂至极”：生物制药领袖痛批监管乱象
'Bat-sh*t crazy': Biopharma leaders unload on regulatory chaos
恒瑞医药与凯莱英凭借中国中期数据积极推动减肥药研发。
Hengrui, Kailera push obesity pill ahead on promising mid-stage China data
FDA拒绝批准Regenxbio的亨特综合征基因疗法。
FDA rejects Regenxbio's Hunter syndrome gene therapy